POTASH CORPORATION OF SASKATCHEWAN INC. TERMS AGREEMENT Debt Securities
Exhibit 1(a)
POTASH CORPORATION OF SASKATCHEWAN INC.
Debt Securities
September 23, 2009
To: The Underwriters identified herein
Ladies and Gentlemen:
The undersigned Potash Corporation of Saskatchewan Inc. (the “Company”) agrees to sell to the
several Underwriters named in Schedule A hereto for their respective accounts, on and subject to
the terms and conditions of the Underwriting Agreement attached hereto as Exhibit I (the
“Underwriting Agreement”), the following securities (the “Offered Securities”) on the following
terms:
Title: 3.75% Notes due September 30, 2015 (the “2015 Notes”); 4.875% Notes due March 30, 2020
(the “2020 Notes”)
Principal Amount: $500,000,000 aggregate principal amount of 2015 Notes; $500,000,000
aggregate principal amount of 2020 Notes
Interest: 3.75% per annum from September 28, 2009 in the case of the 2015 Notes and 4.875% per
annum from September 28, 2009 in the case of the 2020 Notes, in each case payable semiannually on
March 30 and September 30, commencing March 30, 2010, to holders of record on the preceding March
15 or September 15, as the case may be
Maturity: September 30, 2015 in the case of the 2015 Notes; March 30, 2020 in the case of the
2020 Notes
Optional Redemption: The Offered Securities of each series will be redeemable, in whole or in
part, at the option of the Company at any time and from time to time at a redemption price equal to
the greater of (i) 100% of the principal amount of the Offered Securities to be redeemed and (ii)
the sum of the present values of the remaining scheduled payments discounted to the date of
redemption on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at
the adjusted treasury rate plus 25 basis points in the case of the 2015 Notes and 25 basis points
in the case of the 2020 Notes, together with, in each case, accrued interest on the principal
amount of the Offered Securities to be redeemed to the date of redemption, as more fully described
in the Company’s final prospectus supplement, dated September 23, 2009 (the “Final Prospectus
Supplement”)
Listing: None
Delayed Delivery Contracts: None
Lock-up Period (pursuant to Section 4(j) of the Underwriting Agreement): From the date hereof
through September 28, 2009
Underwriting Fee: 0.600% of the principal amount in the case of the 2015 Notes; 0.650% of the
principal amount in the case of the 2020 Notes
Payment by Underwriters: 98.852% of the principal amount, plus accrued interest, if any, from
September 28, 2009 in the case of the 2015 Notes; 98.459% of the principal amount, plus accrued
interest, if any, from September 28, 2009 in the case of the 2020 Notes
Expected Reoffering Price: 99.452% of the principal amount in the case of the 2015 Notes and
99.109% of the principal amount in the case of the 2020 Notes, in each case subject to change by
the Representatives
Applicable Time: 2:30 p.m. (Eastern Time) on the date of this Terms Agreement
Final Term Sheet: The Company will prepare and file a final term sheet relating to the
Offered Securities as contemplated in
Section
4(c) of the Underwriting Agreement
4(c) of the Underwriting Agreement
Closing: 8:30 a.m. (Eastern Time) on September 28, 2009, at the offices of Xxxxx Day, 00 Xxxx
Xxxxxx, Xxxxxxx, Xxxxxxxx, in Federal (same day) funds
Settlement and Trading: Book-Entry only via DTC
Lead Underwriter: Banc of America Securities LLC
Representatives: Banc of America Securities LLC, HSBC Securities (USA) Inc. and RBC Capital
Markets Corporation
The respective principal amounts of the Offered Securities to be purchased by each of the
Underwriters are set forth opposite their names in Schedule A hereto.
The provisions of the Underwriting Agreement form a part hereof.
For purposes of Sections 2, 5 and 7 of the Underwriting Agreement, the only information
furnished to the Company by any Underwriter for use in the General Disclosure Package (as defined
in the Underwriting Agreement) or the Final Prospectus Supplement consists of the following
information in the Company’s preliminary prospectus supplement, dated September 23, 2009 (the
“Preliminary Prospectus Supplement”), and the Final Prospectus Supplement:
(i) | the information in the third sentence under the caption “Risk Factors — The notes have no prior public market and we cannot assure you that any public market will develop or be sustained after the offering” in the Preliminary Prospectus Supplement and the Final Prospectus Supplement; | ||
(ii) | the information in the first and second sentences of the fifth paragraph under the caption “Underwriting” in the Preliminary Prospectus Supplement and the Final Prospectus Supplement; and | ||
(iii) | the information in the third sentence of the eighth paragraph under the caption “Underwriting” in the Preliminary Prospectus Supplement and the Final Prospectus Supplement. |
2
If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company one of the counterparts hereof, whereupon it will become a binding agreement
between the Company and the several Underwriters in accordance with its terms.
Very truly yours, | ||||||
POTASH CORPORATION OF SASKATCHEWAN INC. | ||||||
By: | /s/ Xxxxx X. Xxxxxxxx | |||||
Name: | Xxxxx X. Xxxxxxxx
|
|||||
Title: | Executive Vice President, Treasurer and Chief Financial Officer | |||||
By: | /s/ Xxxxx X. Xxxxxx | |||||
Name: | Xxxxx X. Xxxxxx
|
|||||
Title: | Vice President and Corporate Controller |
The foregoing Terms Agreement is hereby confirmed
and accepted as of the date first above written.
and accepted as of the date first above written.
BANC OF AMERICA SECURITIES LLC | ||||
By: |
/s/ Xxxxxx Xxxxxxxx | |||
on behalf of itself and as Lead Underwriter of the several Underwriters |
||||
Name: |
Xxxxxx Xxxxxxxx | |||
Title: |
Managing Director |
3
SCHEDULE A TO TERMS AGREEMENT
Principal Amount | Principal Amount | ||||||||
Underwriter | of 2015 Notes | of 2020 Notes | |||||||
Banc of America Securities LLC |
$ | 125,000,000 | $ | 125,000,000 | |||||
HSBC Securities (USA) Inc. |
80,000,000 | 80,000,000 | |||||||
RBC Capital Markets Corporation |
80,000,000 | 80,000,000 | |||||||
Scotia Capital (USA) Inc. |
65,000,000 | 65,000,000 | |||||||
BMO Capital Markets Corp. |
65,000,000 | 65,000,000 | |||||||
CIBC World Markets Corp. |
15,000,000 | 15,000,000 | |||||||
Rabo Securities USA, Inc. |
15,000,000 | 15,000,000 | |||||||
TD Securities (USA) LLC |
15,000,000 | 15,000,000 | |||||||
UBS Securities LLC |
15,000,000 | 15,000,000 | |||||||
Mitsubishi UFJ Securities (USA), Inc. |
6,250,000 | 6,250,000 | |||||||
SG Americas Securities, LLC |
6,250,000 | 6,250,000 | |||||||
Comerica Securities, Inc. |
6,250,000 | 6,250,000 | |||||||
Xxxxxxx, Xxxxx & Co. |
3,250,000 | 3,250,000 | |||||||
Xxxxxx Xxxxxxx & Co. Incorporated |
3,000,000 | 3,000,000 | |||||||
Total |
$ | 500,000,000 | $ | 500,000,000 | |||||
4
SCHEDULE B TO TERMS AGREEMENT
(referred to in Sections 2 and 5 of the Underwriting Agreement)
1. | Statutory Prospectus included in the General Disclosure Package | |
1. Base Prospectus, dated December 12, 2007, as supplemented by the Preliminary Prospectus Supplement | ||
2. | General Use Issuer Free Writing Prospectuses (included in the General Disclosure Package) | |
“General Use Issuer Free Writing Prospectus” includes each of the following documents: | ||
1. Final term sheet, dated September 23, 2009, a copy of which is attached hereto | ||
3. | Issuer Free Writing Prospectus |
The use of each of the following Issuer Free Writing Prospectuses has been consented to by the
Company and the Representatives pursuant to Section 5(a)(iii) of the Underwriting Agreement:
None.
5
FINAL TERM SHEET
Issuer:
|
Potash Corporation of Saskatchewan Inc. | |
Title of Securities:
|
3.75% Notes due September 30, 2015 | |
Expected Ratings:
|
Baa1 / A- (Stable/Negative) | |
Format:
|
SEC Registered — Registration Statement No. 333-148023 | |
Ranking:
|
Senior Unsecured | |
Principal Amount:
|
$500,000,000 | |
Expected Settlement Date:
|
September 28, 2009 | |
Trade Date:
|
September 23, 2009 | |
Maturity Date:
|
September 30, 2015 | |
Interest Payment Dates:
|
March 30 and September 30 of each year | |
First Payment Date:
|
March 30, 2010 | |
Benchmark Treasury:
|
2.375% due August 31, 2014 | |
Benchmark Treasury Price:
|
99-20+ | |
Benchmark Treasury Yield:
|
2.453% | |
Spread to Benchmark Treasury:
|
T + 140 basis points | |
Reoffer Yield:
|
3.853% | |
Coupon:
|
3.75% payable semi-annually | |
Price to Public:
|
99.452% | |
Day Count:
|
30/360 | |
Minimum Denominations:
|
$2,000 x $1,000 | |
Redemption Make Whole:
|
At any time at the adjusted treasury rate plus 25 basis points | |
CUSIP Number / ISIN Number:
|
00000XXX0 / US73755LAG23 | |
Joint Book-Running Managers:
|
Banc of America Securities LLC | |
HSBC Securities (USA) Inc. | ||
RBC Capital Markets Corporation | ||
Co-Managers:
|
Scotia Capital (USA) Inc. | |
BMO Capital Markets Corp. | ||
CIBC World Markets Corp. | ||
Rabo Securities USA, Inc. | ||
TD Securities (USA) LLC | ||
UBS Securities LLC | ||
Mitsubishi UFJ Securities (USA), Inc. | ||
SG Americas Securities, LLC | ||
Comerica Securities, Inc. | ||
Xxxxxxx, Sachs & Co. | ||
Xxxxxx Xxxxxxx & Co. Incorporated |
Issuer:
|
Potash Corporation of Saskatchewan Inc. | |
Title of Securities:
|
4.875% Notes due March 30, 2020 | |
Expected Ratings:
|
Baa1 / A- (Stable/Negative) | |
Format:
|
SEC Registered — Registration Statement No. 333-148023 | |
Ranking:
|
Senior Unsecured | |
Principal Amount:
|
$500,000,000 | |
Expected Settlement Date:
|
September 28, 2009 | |
Trade Date:
|
September 23, 2009 | |
Maturity Date:
|
March 30, 2020 | |
Interest Payment Dates:
|
March 30 and September 30 of each year | |
First Payment Date:
|
March 30, 2010 | |
Benchmark Treasury:
|
3.625% due August 15, 2019 | |
Benchmark Treasury Price:
|
101-05 | |
Benchmark Treasury Yield:
|
3.485% | |
Spread to Benchmark Treasury:
|
T + 150 basis points | |
Reoffer Yield:
|
4.985% | |
Coupon:
|
4.875% payable semi-annually | |
Price to Public:
|
99.109% | |
Day Count:
|
30/360 | |
Minimum Denominations:
|
$2,000 x $1,000 | |
Redemption Make Whole:
|
At any time at the adjusted treasury rate plus 25 basis points | |
CUSIP Number / ISIN Number:
|
00000XXX0 / US73755LAH06 | |
Joint Book-Running Managers:
|
Banc of America Securities LLC | |
HSBC Securities (USA) Inc. | ||
RBC Capital Markets Corporation | ||
Co-Managers:
|
Scotia Capital (USA) Inc. | |
BMO Capital Markets Corp. | ||
CIBC World Markets Corp. | ||
Rabo Securities USA, Inc. | ||
TD Securities (USA) LLC | ||
UBS Securities LLC | ||
Mitsubishi UFJ Securities (USA), Inc. | ||
SG Americas Securities, LLC | ||
Comerica Securities, Inc. | ||
Xxxxxxx, Sachs & Co. | ||
Xxxxxx Xxxxxxx & Co. Incorporated |
A securities rating is not a recommendation to buy, sell or hold securities and may be subject to
revision or withdrawal at any time.
The Issuer has filed a Registration Statement on Form S-3 (including a base prospectus dated
December 12, 2007, as supplemented by a preliminary prospectus supplement, dated September 23,
2009, the “Prospectus”) with the SEC for the offering to which this communication relates. Before
you invest, you should read the Prospectus and the
7
documents incorporated therein by reference that the Issuer has filed with the SEC for more
complete information about the Issuer and this offering. You may obtain these documents for free by
visiting XXXXX on the SEC website at xxx.xxx.xxx. Alternatively, the Issuer, any underwriter or any
dealer participating in the offering will arrange to send you the Prospectus and any document
incorporated by reference in the Prospectus if you request it by calling toll-free 1-800-294-1322
or you may e-mail a request to
xx.xxxxxxxxxx_xxxxxxxxxxxx@xxxxxxxxxxxxxx.xxx, HSBC Securities (USA)
Inc. toll-free at
0-000-000-0000 or RBC Capital Markets Corporation toll-free at 0-000-000-0000.
Any legends, disclaimers or other notices that may appear below are not applicable to this
communication and should be disregarded. Such legends, disclaimers or other notices have been
automatically generated as a result of this communication having been sent via Bloomberg or another
system.
8
EXHIBIT I
POTASH CORPORATION OF SASKATCHEWAN INC.
UNDERWRITING AGREEMENT
UNDERWRITING AGREEMENT
Debt Securities
1. Introductory. Potash Corporation of Saskatchewan Inc., a corporation continued and existing
under the laws of Canada (the “Company”), proposes to issue and sell from time to time certain of
its unsecured debt securities (the “Registered Securities”) registered under the registration
statement referred to in Section 2(a). The Registered Securities will be issued under an indenture,
dated as of February 27, 2003 (the “Indenture”), between the Company and The Bank of Nova Scotia
Trust Company of New York, as trustee, in one or more series, which series may vary as to interest
rates, maturities, redemption provisions, selling prices and other terms, with all such terms for
any particular series of the Registered Securities being determined at the time of sale. Particular
series of the Registered Securities will be sold pursuant to a Terms Agreement referred to in
Section 3, for resale in accordance with terms of offering determined at the time of sale.
The Registered Securities involved in any such offering are hereinafter referred to as the
“Offered Securities”. The firm or firms that agree to purchase the Offered Securities are
hereinafter referred to as the “Underwriters” of such securities, and the representative or
representatives of the Underwriters, if any, specified in a Terms Agreement referred to in Section
3 are hereinafter referred to as the “Representatives”; provided, however, that if the Terms
Agreement does not specify any representative of the Underwriters, the term “Representatives”, as
used in this Agreement (other than in Sections 2(b), 5(c) and 7 and the second sentence of Section
3), shall mean the Underwriters.
2. Representations and Warranties of the Company. The Company, as of the date of each Terms
Agreement referred to in Section 3, represents and warrants to, and agrees with, each Underwriter
that:
(a) Registration Statement Effective. An “automatic shelf registration statement” as defined
under Rule 405 under the Securities Act of 1933, as amended (the “Securities Act”), on Form S-3
(File No. 333-148023) in respect of the Offered Securities has been filed with the Securities and
Exchange Commission (the “Commission”); such registration statement, and any post-effective
amendment thereto, became effective on filing; and no stop order suspending the effectiveness of
such registration statement or any part thereof has been issued and no proceeding for that purpose
has been initiated or threatened by the Commission (the base prospectus filed as part of the
Registration Statement, in the form in which it has been most recently filed with the Commission on
or prior to the date of any Terms Agreement referred to in Section 3, is hereinafter called the
“Base Prospectus”; any preliminary prospectus (including any preliminary prospectus supplement)
relating to the Offered Securities filed with the Commission pursuant to and in accordance with
Rule 424(b) under the Securities Act prior to the filing of the Prospectus is hereinafter called a
“Preliminary Prospectus”; the various parts of such registration statement, including all exhibits
thereto but excluding the Form T-1 and including any information in a prospectus or prospectus
supplement relating to the Offered Securities that is filed with the Commission and deemed or
retroactively deemed by virtue of Rule 430B under the Securities Act to be part of such
registration statement (“430B Information”), each as amended at the time such part of the
registration statement became effective, are hereinafter collectively called the “Registration
Statement”; the Base Prospectus, as amended and supplemented (including by a Preliminary
Prospectus) immediately prior to the Applicable Time (as defined in any Terms Agreement referred to
in Section 3), is hereinafter called the “Statutory Prospectus”; the form of the final prospectus
relating to the Offered Securities that discloses the public offering price and other 430B
Information and other final terms of the Offered Securities and otherwise satisfies the
requirements of Section 10(a) of the Securities Act, filed with the
Commission pursuant to Rule 424(b) under the Securities Act in accordance with Section 4(a)
hereof is hereinafter called the “Prospectus”; any reference herein to the Base Prospectus, the
Statutory Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and
include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 under the
Securities Act, as of the date of such prospectus; any reference to any amendment or supplement to
the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and
include any post-effective amendment to the Registration Statement, any prospectus supplement
relating to the Offered Securities filed with the Commission pursuant to Rule 424(b) under the
Securities Act and any documents filed under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), and incorporated therein, in each case after the date of the Base Prospectus, such
Preliminary Prospectus, or the Prospectus, as the case may be; any reference to any amendment to
the Registration Statement shall be deemed to refer to and include any annual report of the Company
filed pursuant to Section 13(a) or 15(d) of the Exchange Act after the effective date of the
Registration Statement that is incorporated by reference in the Registration Statement; any Issuer
Free Writing Prospectus that is intended for general distribution to prospective investors, as
evidenced by its being so specified in Schedule B to the Terms Agreement is hereinafter referred to
as a “General Use Issuer Free Writing Prospectus”; any “issuer free writing prospectus”, as
defined in Rule 433 under the Securities Act, relating to the Offered Securities in the form filed
or required to be filed with the Commission or, if not required to be filed, in the form retained
in the Company’s records pursuant to Rule 433(g) under the Securities Act is hereinafter referred
to as a “Issuer Free Writing Prospectus”; and any Issuer Free Writing Prospectus that is not a
General Use Issuer Free Writing Prospectus is hereinafter referred to as a “Limited Use Issuer Free
Writing Prospectus”.
(b) Registration Statement and Prospectus Not Misleading. No order preventing or suspending
the use of any Preliminary Prospectus or any Issuer Free Writing Prospectus has been issued by the
Commission, and (i) each Preliminary Prospectus, at the time of filing thereof, conformed in all
material respects to the requirements of the Securities Act and the Trust Indenture Act of 1939, as
amended (“Trust Indenture Act”), and the rules and regulations of the Commission thereunder and did
not include any untrue statement of a material fact or omit to state any material fact required to
be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading, and (ii) at the Applicable Time, the Registration
Statement conforms, and any further amendments to the Registration Statement will conform, in all
material respects to the requirements of the Securities Act, the Trust Indenture Act and the rules
and regulations of the Commission thereunder, and does not and will not include any untrue
statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein, not misleading and (iii) the Prospectus, and any further
amendments or supplements to the Prospectus will conform (A) on its date, (B) at the time of filing
the Prospectus pursuant to Rule 424(b) and (C) on the closing date with respect to the Offered
Securities, in all material respects to the requirements of the Securities Act, the Trust Indenture
Act and the rules and regulations of the Commission thereunder, and will not include any untrue
statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading, except that the foregoing does not apply to statements in or omissions from
any of such documents based upon written information furnished to the Company by any Underwriter
through the Representatives, if any, specifically for use therein.
(c) General Disclosure Package. For the purposes of this Agreement, the “Applicable Time” is
the time set forth in the applicable Terms Agreement referred to in Section 3; as of the Applicable
Time, neither (i) the General Use Issuer Free Writing Prospectus(es) issued at or prior to the
Applicable Time, the Statutory Prospectus identified in Schedule B to the Terms Agreement attached
hereto (which is the most recent Statutory Prospectus distributed to investors generally) and any
other documents listed or information stated in Schedule B to the Terms Agreement attached hereto
to be included in the General Disclosure Package, all considered together (collectively, the
“General Disclosure Package”) or (ii) any
10
individual Limited Use Issuer Free Writing Prospectus, when considered together with the
General Disclosure Package, included any untrue statement of a material fact or omitted to state
any material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; and each Issuer Free Writing Prospectus
does not conflict with the information contained in the Registration Statement, the Statutory
Prospectus or the Prospectus and each such Issuer Free Writing Prospectus, as supplemented by and
taken together with the General Disclosure Package as of the Applicable Time, did not include any
untrue statement of a material fact or omit to state any material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not
misleading; provided, however, that this representation and warranty shall not apply to statements
or omissions made in the General Disclosure Package or an Issuer Free Writing Prospectus in
reliance upon and in conformity with information furnished in writing to the Company by an
Underwriter through the Representatives expressly for use therein.
(d) Documents Incorporated by Reference. The documents incorporated by reference in the
Statutory Prospectus and the Prospectus, when they became effective or were filed with the
Commission, as the case may be, conformed in all material respects to the requirements of the
Securities Act or the Exchange Act, as applicable, and the rules and regulations of the Commission
thereunder, and none of such documents included any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading; any further documents
so filed and incorporated by reference in the Prospectus or any further amendment or supplement
thereto, when such documents become effective or are filed with the Commission, as the case may be,
will conform in all material respects to the requirements of the Securities Act or the Exchange
Act, as applicable, and the rules and regulations of the Commission thereunder and will not include
any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading; except that the foregoing does
not apply to statements in or omissions from any of such documents based upon written information
furnished to the Company by any Underwriter through the Representatives, if any, specifically for
use therein; and no such documents were filed with the Commission since the Commission’s close of
business on the business day immediately prior to the date of this Agreement and prior to the
execution of this Agreement.
(e) Taxation. Subject to the assumptions, limitations, qualifications and conditions set forth
therein, the statements made in the General Disclosure Package and the Prospectus under the
headings “United States Federal Income Tax Considerations”, insofar as they relate to matters of
United States federal income tax law, and “Canadian Federal Income Tax Considerations”, insofar as
they relate to matters of Canadian federal income tax law, constitute a fair summary of the matters
so discussed and applicable to the holders of Offered Securities described therein.
(f) Incorporation of the Company. The Company has been continued and is an existing
corporation under the laws of Canada, with power and authority (corporate and other) to own its
properties and conduct its business as described in the General Disclosure Package and the
Prospectus; and the Company is duly qualified or registered to do business in all other
jurisdictions in which its ownership or lease of property or the conduct of its business requires
such qualification or registration, except where the failure to be so qualified or registered would
not individually or in the aggregate have a material adverse effect on the financial condition,
business, properties or results of operations of the Company and its subsidiaries taken as one
enterprise (a “Material Adverse Effect”).
(g) Organization of Subsidiaries. Each material subsidiary of the Company is set forth on
Schedule A hereto (each, a “Subsidiary”). Each Subsidiary is a corporation or limited partnership
duly incorporated or organized, as the case may be, existing in good standing under the laws of the
jurisdiction of its incorporation or organization, with power and authority (corporate and other)
to own its properties
11
and conduct its business as described in the General Disclosure Package and the Prospectus;
and each Subsidiary is duly qualified or registered to do business as a foreign corporation or
limited partnership in good standing in all other jurisdictions in which its ownership or lease of
property or the conduct of its business requires such qualification or registration, except where
the failure to be so qualified or registered would not individually or in the aggregate have a
Material Adverse Effect; all of the issued and outstanding capital stock of each Subsidiary has
been duly authorized and validly issued and is fully paid and nonassessable; and the capital stock
of each Subsidiary is owned directly or indirectly by the Company free from liens, encumbrances and
defects incurred or arising otherwise than in the ordinary course of business.
(h) Authorization of Indenture and Offered Securities. The Indenture has been duly authorized,
executed and delivered and has been duly qualified under the Trust Indenture Act; the Offered
Securities have been duly authorized; and when the Offered Securities are delivered and paid for
pursuant to the Terms Agreement on the Closing Date (as defined below) or pursuant to Delayed
Delivery Contracts (as defined below), such Offered Securities will have been duly executed,
authenticated, issued and delivered, will conform in all material respects to the description
thereof contained in the General Disclosure Package, the Prospectus and the Indenture, and such
Offered Securities will constitute valid and legally binding obligations of the Company,
enforceable in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and similar laws of general applicability relating to or affecting
creditors’ rights and to general equity principles.
(i) No Consents. No consent, approval, authorization, or order of, or filing with, any
governmental agency or body or any court is required for the consummation by the Company of the
transactions contemplated by the Terms Agreement (including the provisions of this Agreement) in
connection with the issuance and sale of the Offered Securities by the Company, except such as have
been obtained and made under the Securities Act and the Trust Indenture Act and such as may be
required under state securities laws or the securities laws of any jurisdiction outside the United
States in which the Offered Securities are offered and sold.
(j) No Breach or Default. The execution, delivery and performance by the Company of the
Indenture, the Terms Agreement (including the provisions of this Agreement) and any Delayed
Delivery Contracts and the issuance and sale of the Offered Securities and compliance with the
terms and provisions thereof by the Company will not conflict with or result in a breach or
violation of any of the terms and provisions of, or constitute a default or acceleration of payment
under, any statute, any rule, regulation or order of any governmental agency or body or any court,
domestic or foreign, having jurisdiction over the Company or any Subsidiary or any of their
properties, or any material agreement or instrument to which the Company or any Subsidiary is a
party or by which the Company or any Subsidiary is bound or to which any of the properties of the
Company or any Subsidiary is subject, or the charter or by-laws of the Company or any Subsidiary.
(k) Authorization of Terms Agreement. The Terms Agreement (including the provisions of this
Agreement) and any Delayed Delivery Contracts have been duly authorized, executed and delivered by
the Company.
(l) Properties. Except as disclosed in the General Disclosure Package and the Prospectus, the
Company and the Subsidiaries have good and marketable title to all real properties and all other
properties and assets described in the General Disclosure Package and the Prospectus as being owned
by them, in each case free from liens, encumbrances and defects that would materially affect the
value thereof or materially interfere with the use made or to be made thereof by them, except to
the extent that the failure to hold any such title would not have a Material Adverse Effect; and,
except as disclosed in the General Disclosure Package and the Prospectus, the Company and the
Subsidiaries hold any leased real or
12
personal property described in the General Disclosure Package and the Prospectus as being
leased by them under valid and enforceable leases with no exceptions that would materially
interfere with the use made or to be made thereof by them, except to the extent that the failure so
to hold any such leased property would not individually or in the aggregate have a Material Adverse
Effect.
(m) Permits. Except as disclosed in the General Disclosure Package and the Prospectus, the
Company and the Subsidiaries possess adequate certificates, approvals, licenses, franchises,
authorizations or permits (collectively, “Permits”) issued by appropriate governmental agencies or
bodies necessary to conduct the business now operated by them, except where the failure to have any
such Permit would not individually or in the aggregate have a Material Adverse Effect; and, except
as disclosed in the General Disclosure Package and the Prospectus, the Company and the Subsidiaries
have not received any notice of proceedings relating to the revocation or modification of any
Permit that, if determined adversely to the Company or any of the Subsidiaries, would individually
or in the aggregate have a Material Adverse Effect.
(n) Labor. No labor dispute with the employees of the Company or any Subsidiary exists or, to
the knowledge of the Company, is threatened that would have a Material Adverse Effect.
(o) Intellectual Property. The Company and the Subsidiaries own, possess or can acquire on
reasonable terms, adequate trademarks, trade names and other rights to inventions, know-how,
patents, copyrights, confidential information and other intellectual property (collectively,
“Intellectual Property Rights”) presently employed by them or necessary to conduct the business now
operated by them, and have not received any notice of infringement of or conflict with asserted
rights of others with respect to any Intellectual Property Rights that, if determined adversely to
the Company or any of the Subsidiaries, would individually or in the aggregate have a Material
Adverse Effect.
(p) Environmental Laws. Except as disclosed in the General Disclosure Package and the
Prospectus, neither the Company nor any of the Subsidiaries is in violation of any statute, rule,
regulation, decision or order of any governmental agency or body or any court, domestic or foreign,
relating to the use, disposal or release of hazardous or toxic substances or relating to the
protection or restoration of the environment or human exposure to hazardous or toxic substances
(collectively, “Environmental Laws”), owns or operates any real property contaminated with any
substance required to be remediated under any Environmental Laws, or, to the Company’s knowledge,
is liable for any off-site disposal or contamination pursuant to any Environmental Laws or is
subject to any claim under any Environmental Laws, which violation, contamination, liability or
claim would individually or in the aggregate have a Material Adverse Effect; and, except as
disclosed in the General Disclosure Package and the Prospectus, the Company is not aware of any
pending investigation that would be likely to lead to such a claim. In addition, based upon the
Company’s reviews, conducted in the ordinary course of its business, of the effect of Environmental
Laws on the business and operations of the Company and the Subsidiaries, the Company has reasonably
concluded that, except as disclosed in the General Disclosure Package and the Prospectus, the costs
and liabilities under Environmental Laws currently in effect (including, without limitation, any
capital or operating expenditures required for clean-up, closure or rehabilitation of properties or
compliance with Environmental Laws or any Permit, any related constraints on operating activities
and potential liabilities to third parties) would not, individually or in the aggregate, have a
Material Adverse Effect.
(q) No Material Litigation. Except as disclosed in the General Disclosure Package and the
Prospectus, there are no pending actions, suits or proceedings against or affecting the Company,
any of the Subsidiaries or any of their respective properties that, if determined adversely to the
Company or any of its Subsidiaries, would individually or in the aggregate have a Material Adverse
Effect, or would materially and adversely affect the ability of the Company to perform its
obligations under the Indenture,
13
the Terms Agreement (including the provisions of this Agreement) or any Delayed Delivery
Contracts; and no such actions, suits or proceedings are, to the Company’s knowledge, threatened.
(r) Financial Statements. The financial statements included in the Registration Statement, the
General Disclosure Package and the Prospectus present fairly the financial position of the Company
and its consolidated subsidiaries as of the dates shown and their results of operations and cash
flows for the periods shown, and such financial statements have been prepared in conformity with
accounting principles generally accepted in Canada applied on a consistent basis throughout the
periods presented, except as otherwise noted therein; and any schedules included in the
Registration Statement present fairly the information required to be stated therein. Such financial
statements have also been reconciled to accounting principles generally accepted in the United
States in accordance with the requirements of the Securities Act and the rules and regulations
thereunder.
(s) No Material Adverse Change. Except as disclosed in the General Disclosure Package and the
Prospectus, since the date of the latest audited financial statements included in the General
Disclosure Package, there has been no material adverse change, nor any development or event
involving a prospective material adverse change, in the financial condition, business, properties
or results of operations of the Company and its subsidiaries taken as one enterprise; and, except
as disclosed or contemplated in the General Disclosure Package and the Prospectus, and other than
the Company’s ordinary quarterly dividends, there has been no other dividend or distribution of any
kind declared, paid or made by the Company on any class of its capital stock.
(t) Investment Company Act. The Company is not and, after giving effect to the offering and
sale of the Offered Securities and the application of the proceeds thereof as described in the
Prospectus and the General Disclosure Package, will not be an “investment company’’ as defined in
the Investment Company Act of 1940.
(u) Internal Controls and Compliance with the Xxxxxxxx-Xxxxx Act. There is no failure on the
part of the Company, its subsidiaries or the Company’s Board of Directors to comply in all material
respects with the applicable provisions of the Xxxxxxxx-Xxxxx Act of 2002 and the applicable rules
and regulations of the New York Stock Exchange. The Company has devised and established and
maintains the following, among other, internal controls (without duplication): (x) a system of
“internal accounting controls” as contemplated by Section 13(b)(2)(B) of the Exchange Act and (y)
“internal control over financial reporting” (as such term is defined in Rule 13a-15(f) under the
Exchange Act) that comply with the requirements of the Exchange Act and are sufficient to provide
reasonable assurances that (i) transactions are executed in accordance with management’s general or
specific authorizations, (ii) transactions are recorded as necessary to permit preparation of
financial statements in conformity with accounting principles generally accepted in Canada and to
maintain accountability for assets, (iii) access to assets is permitted only in accordance with
management’s general or specific authorization and (iv) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action is taken with
respect to any differences. Such internal controls are overseen by the Audit Committee of the Board
in all material respects in accordance with the rules and regulations under the Exchange Act.
Except as disclosed in the General Disclosure Package and the Prospectus, there are no material
weaknesses in the Company’s internal control over financial reporting, and there has been no change
in the Company’s internal control over financial reporting that has materially affected, or is
reasonably likely to materially affect, the Company’s internal control over financial reporting.
The Company employs disclosure controls and procedures (as such term is defined in Rule
13a-15(e) under the Exchange Act) that are designed to ensure that information required to be
disclosed by the Company in the reports that it files or submits under the Exchange Act is
recorded, processed, summarized and reported, within the time periods specified in the Commission’s
rules and forms, and is
14
accumulated and communicated to the Company’s management, as appropriate, to allow timely
decisions regarding disclosure.
(v) Well-Known Seasoned Issuer. (i) At the earliest time after the filing of the Registration
Statement that the Company or another offering participant made a bona fide offer (within the
meaning of Rule 164(h)(2) under the Securities Act) of the Offered Securities and (ii) at the date
of the Terms Agreement, the Company was not and is not an “ineligible issuer,” as defined in Rule
405 (“Rule 405”) under the Securities Act, including (x) the Company or any other subsidiary in the
preceding three years not having been convicted of a felony or misdemeanor or having been made the
subject of a judicial or administrative decree or order as described in Rule 405 and (y) the
Company in the preceding three years not having been the subject of a bankruptcy petition or
insolvency or similar proceeding, not having had a registration statement be the subject of a
proceeding under Section 8 of the Securities Act and not being the subject of a proceeding under
Section 8A of the Securities Act in connection with an offering of securities, all as described in
Rule 405. (A) At the time of the initial filing of the Registration Statement, (B) at the time of
the most recent amendment thereto for the purposes of complying with Section 10(a)(3) of the
Securities Act (whether such amendment was by post-effective amendment, incorporated report filed
pursuant to Section 13 or 15(d) of the Exchange Act or form of prospectus) and (C) at the time the
Company or any person acting on its behalf (within the meaning, for this clause only, of Rule
163(c) under the Securities Act) made any offer relating to the Offered Securities in reliance on
the exemption provided by Rule 163 under the Securities Act, the Company was a “well known seasoned
issuer” as defined in Rule 405, including not having been an “ineligible issuer” as defined in Rule
405.
(w) Eligibility to Use Automatic Shelf Registration Form. The Company has not received from
the Commission any notice pursuant to Rule 401(g)(2) under the Securities Act objecting to use of
the automatic shelf registration statement form. If at any time when Offered Securities remain
unsold by the Underwriters the Company receives from the Commission a notice pursuant to Rule
401(g)(2) under the Securities Act or otherwise ceases to be eligible to use the automatic shelf
registration statement form, the Company will (i) promptly notify the Lead Underwriter, (ii)
promptly file a new registration statement or post-effective amendment on the proper form relating
to the Offered Securities, in a form satisfactory to the Lead Underwriter, (iii) use its best
efforts to cause such registration statement or post-effective amendment to be declared effective
as soon as practicable and (iv) promptly notify the Lead Underwriter of such effectiveness. The
Company will take all other action necessary or appropriate to permit the public offering and sale
of the Offered Securities to continue as contemplated in the registration statement that was the
subject of the Rule 401(g)(2) notice or for which the Company has otherwise become ineligible.
References herein to the Registration Statement shall include such new registration statement or
post-effective amendment, as the case may be.
3. Purchase and Offering of Offered Securities. The obligation of the Underwriters to purchase
the Offered Securities will be evidenced by an agreement (the “Terms Agreement”) at the time the
Company determines to sell the Offered Securities. The Terms Agreement will incorporate by
reference the provisions of this Agreement, except as otherwise provided therein, and will specify
the firm or firms that will be the Underwriters, the names of any Representatives, the principal
amount to be purchased by each Underwriter, the purchase price to be paid by the Underwriters and
the terms of the Offered Securities not already specified in the Indenture, including, but not
limited to, interest rate, maturity, any redemption provisions and any sinking fund requirements
and whether any of the Offered Securities may be sold to institutional investors pursuant to
Delayed Delivery Contracts (as defined below). The Terms Agreement will also specify the time and
date of delivery and payment (such time and date, or such other time not later than seven full
business days thereafter as the Underwriter first named in the Terms Agreement (the “Lead
Underwriter”) and the Company agree as the time for delivery and payment, being herein and in the
Terms Agreement referred to as the “Closing Date”), the place of delivery and payment and any
details of the terms of offering that should be reflected in the prospectus supplement
15
relating to the offering of the Offered Securities. For purposes of Rule 15c6-1 under the
Exchange Act, the Closing Date (if later than the otherwise applicable settlement date) shall be
the date for payment of funds and delivery of securities for all the Offered Securities sold
pursuant to the offering, other than Contract Securities (as defined below) for which payment of
funds and delivery of securities shall be as hereinafter provided. The obligations of the
Underwriters to purchase the Offered Securities will be several and not joint. It is understood
that the Underwriters propose to offer the Offered Securities for sale as set forth in the
Prospectus.
On the Closing Date, the Company will pay, as an underwriting fee in respect of the public
distribution of the Offered Securities, to the Underwriters, the fee set forth in the Terms
Agreement (the “Underwriting Fee”). Such Underwriting Fee may be paid by the Company to the
Underwriters by setting off the Underwriting Fee payable by the Company to the Underwriters against
the amount payable by the Underwriters to the Company as the purchase price for the Offered
Securities.
If the Terms Agreement provides for sales of Offered Securities pursuant to delayed delivery
contracts, the Company authorizes the Underwriters to solicit offers to purchase Offered Securities
pursuant to delayed delivery contracts substantially in the form of Annex I attached hereto
(“Delayed Delivery Contracts”) with such changes therein as the Company may authorize or approve.
Delayed Delivery Contracts are to be with institutional investors, including commercial and savings
banks, insurance companies, pension funds, investment companies and educational and charitable
institutions. On the Closing Date, the Company will pay, as compensation, to the Representatives
for the accounts of the Underwriters, the fee set forth in such Terms Agreement in respect of the
principal amount of Offered Securities to be sold pursuant to Delayed Delivery Contracts (“Contract
Securities”). The Underwriters will not have any responsibility in respect of the validity or the
performance of Delayed Delivery Contracts. If the Company executes and delivers Delayed Delivery
Contracts, the Contract Securities will be deducted from the Offered Securities to be purchased by
the several Underwriters and the aggregate principal amount of Offered Securities to be purchased
by each Underwriter will be reduced pro rata in proportion to the principal amount of Offered
Securities set forth opposite each Underwriter’s name in such Terms Agreement, except to the extent
that the Lead Underwriter determines that such reduction shall be otherwise than pro rata and so
advises the Company. The Company will advise the Lead Underwriter not later than the business day
prior to the Closing Date of the principal amount of Contract Securities.
If the Terms Agreement specifies “Book-Entry Only” settlement or otherwise states that the
provisions of this paragraph shall apply, the Company will deliver against payment of the purchase
price the Offered Securities in the form of one or more permanent global securities in definitive
form (the “Global Securities”) deposited with the Trustee as custodian for The Depository Trust
Company (“DTC”) and registered in the name of Cede & Co., as nominee for DTC. Interests in any
permanent global securities will be held only in book-entry form through DTC, except in the limited
circumstances described in the Prospectus. Payment for the Offered Securities shall be made by the
Underwriters in Federal (same day) funds by wire transfer to an account previously designated by
the Company at a bank acceptable to the Lead Underwriter, in each case drawn to the order of the
Company at the place of payment specified in the Terms Agreement on the Closing Date, against
delivery to the Trustee as custodian for DTC of the Global Securities representing all of the
Offered Securities.
Each Underwriter agrees that it will not offer or sell, directly or indirectly, any of the
Offered Securities in any jurisdiction where such offer or sale is not permitted. Each Underwriter
further agrees that it will not (i) offer or sell, directly or indirectly, any Offered Securities
in Canada or any province or territory thereof in contravention of the securities laws of Canada or
any province or territory thereof or (ii) distribute any material related to the Offered Securities
in Canada in contravention of the securities laws of Canada or any province or territory thereof.
16
4. Certain Agreements of the Company. The Company agrees with the several Underwriters that it
will furnish to counsel for the Underwriters, one signed copy of the Registration Statement,
including all exhibits, in the form it became effective and of all amendments thereto and that, in
connection with each offering of Offered Securities:
(a) File Prospectus. The Company will file the Prospectus with the Commission pursuant to and
in accordance with Rule 424(b) under the Securities Act not later than the Commission’s close of
business on the second business day following the execution and delivery of the Terms Agreement.
(b) Amendments to Registration Statement or Prospectus. The Company will advise the Lead
Underwriter promptly of any proposal to amend or supplement the Registration Statement, the Base
Prospectus, the Statutory Prospectus or the Prospectus and will afford the Lead Underwriter a
reasonable opportunity to comment on any such proposed amendment or supplement; and the Company
will also advise the Lead Underwriter promptly of the filing of any such amendment or supplement
and of the institution by the Commission of any stop order proceedings in respect of the
Registration Statement or of any part thereof and will use its reasonable best efforts to prevent
the issuance of any such stop order and to obtain as soon as possible its lifting, if issued.
(c) Term Sheet. The Company will prepare a final term sheet relating to the Offered Securities
containing only information that describes the final terms of the Offered Securities and otherwise
in a form consented to by the Lead Underwriter, and will file such final term sheet within the
period required by Rule 433(d)(5)(ii) under the Securities Act following the date such final terms
have been established for all classes of the offering of the Offered Securities. Any such final
term sheet is an Issuer Free Writing Prospectus for purposes of this Agreement. The Company also
consents to the use by any Underwriter of a free writing prospectus that contains only (i)(x)
information describing the preliminary terms of the Offered Securities or their offering or (y)
information that describes the final terms of the Offered Securities or their offering and that is
included in the final term sheet of the Company contemplated in the first sentence of this
subsection or (ii) other information that is not “issuer information,” as defined in Rule 433 under
the Securities Act, it being understood that any such free writing prospectus referred to in clause
(ii) above shall not be an Issuer Free Writing Prospectus for purposes of this Agreement.
(d) Material Changes. If, at any time when a prospectus relating to the Offered Securities is
(or but for the exemption provided by Rule 172 under the Securities Act would be) required to be
delivered under the Securities Act in connection with sales by any Underwriter or dealer, any event
occurs as a result of which the Prospectus as then amended or supplemented would include an untrue
statement of a material fact or omit to state any material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading, or if it is
necessary at any time to amend the Prospectus to comply with the Securities Act, the Company
promptly will notify the Lead Underwriter of such event and will promptly prepare and file with the
Commission, at its own expense, an amendment or supplement that will correct such statement or
omission or an amendment that will effect such compliance. Neither the Lead Underwriter’s consent
to, nor the Underwriters’ delivery of, any such amendment or supplement shall constitute a waiver
of any of the conditions set forth in Section 6 hereof.
(e) Delivery of Earnings Statement. As soon as practicable, but not later than 16 months after
the date of each Terms Agreement, the Company will make generally available to its securityholders
an earnings statement covering a period of at least 12 months beginning after the date of such
Terms Agreement and satisfying the provisions of Section 11(a) and Rule 158 under the Securities
Act.
(f) Delivery of Registration Statement and Prospectus. The Company will furnish to the
Representatives copies of the Registration Statement, including all exhibits, any related
preliminary prospectus supplement, the Prospectus and all amendments and supplements to such
documents, in each
17
case as soon as available and in such quantities as the Lead Underwriter reasonably requests.
The Company will pay the reasonable expenses of printing and distributing to the Underwriters all
such documents; provided that, if any Underwriter is required to deliver a prospectus in connection
with sales of Offered Securities at any time nine months or more after the date of the Prospectus
with respect thereto, the cost of such Prospectus shall be at the expense of such Underwriter.
(g) Qualification of Offered Securities. The Company will cooperate with the Representatives
and with counsel for the Underwriters in connection with the qualification of the Offered
Securities for sale and the determination of their eligibility for investment under the laws of
such jurisdictions in the United States as the Lead Underwriter may reasonably designate and will
continue such qualifications in effect so long as required for the distribution of the Offered
Securities; provided that in no event shall the Company be obligated to qualify to do business in
any jurisdiction where it is not now so qualified, to take any action that would subject it to
service of process in suits, other than those arising out of the offering or sale of the Offered
Securities, in any jurisdiction where it is not now subject or to subject itself to taxation as
doing business in any such jurisdiction.
(h) Expenses. The Company will pay all expenses incident to the performance of its obligations
under the Terms Agreement (including the provisions of this Agreement), any filing fees or other
expenses (including reasonable fees and disbursements of counsel) in connection with qualification
of the Registered Securities for sale and determination of their eligibility for investment under
the laws of such jurisdictions in the United States as the Lead Underwriter may reasonably
designate and the printing of memoranda relating thereto, any fees charged by investment rating
agencies for the rating of the Offered Securities, any applicable filing fee incident to the review
by the Financial Industry Regulatory Authority of the Registered Securities, any travel expenses of
the Company’s officers and employees and any other expenses of the Company in connection with
attending or hosting meetings with prospective purchasers of Registered Securities, expenses
incurred in distributing the Prospectus, any preliminary prospectus supplements or any other
amendments or supplements to the Prospectus to the Underwriters and expenses incurred for
preparing, printing and distributing each Issuer Free Writing Prospectus to investors or
prospective investors.
(i) Taxes. The Company will indemnify and hold harmless the Underwriters against any
documentary, stamp or similar issue tax, under the laws of Canada, including any interest and
penalties payable thereon, payable by the Underwriters on the creation, issue and sale of the
Offered Securities to the Underwriters as contemplated hereby and on the execution and delivery of
the Terms Agreement. All payments to be made by the Company to the Underwriters hereunder shall be
made without withholding or deduction for or on account of any present or future taxes under Part
XIII of the Income Tax Act (Canada), unless the Company is compelled by law to deduct or withhold
such taxes, duties or charges. In the event and to the extent the Underwriters cannot claim or
otherwise take advantage of a tax credit, refund or exemption for Canadian tax withheld, the
Company shall pay such additional amounts as may be necessary in order that the net amounts
received by the Underwriters after such withholding or deduction shall equal the amounts that would
have been received if no withholding or deduction had been made.
(j) Lock-up. The Company will not offer, sell, contract to sell, pledge or otherwise dispose
of, directly or indirectly, or file with the Commission a registration statement under the
Securities Act relating to United States dollar-denominated debt securities issued or guaranteed by
the Company and having a maturity of more than one year from the date of issue, or publicly
disclose the intention to make any such offer, sale, pledge, disposition or filing, without the
prior written consent of the Lead Underwriter for the period, if any, specified in the Terms
Agreement.
18
(k) Use of Proceeds. The Company expects to apply the net proceeds from the sale of the
Offered Securities substantially in accordance with the description set forth in the General
Disclosure Package and the Prospectus.
5. | Free Writing Prospectus. (a)(i) The Company represents and agrees that, other than the final term sheet prepared and filed pursuant to Section 4(c) hereof, without the prior consent of the Representatives, it has not made and will not make any offer relating to the Offered Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a “free writing prospectus” as defined in Rule 405 under the Securities Act; |
(ii) each Underwriter represents and agrees that, without the prior consent of the
Company and the Representatives, other than one or more term sheets relating to the Offered
Securities containing customary information and conveyed to purchasers of Offered
Securities, it has not made and will not make any offer relating to the Offered Securities
that would constitute a “free writing prospectus” as defined in Rule 405 under the
Securities Act, required to be filed with the Commission; and
(iii) any such free writing prospectus the use of which has been consented to by the
Company and the Representatives is listed on Schedule B to the Terms Agreement;
(b) The Company has complied and will comply with the requirements of Rule 433 and Rule 164
under the Securities Act applicable to any Issuer Free Writing Prospectus, including timely filing
with the Commission or retention where required and legending; and
(c) The Company agrees that if at any time following issuance of an Issuer Free Writing
Prospectus any event occurred or occurs as a result of which such Issuer Free Writing Prospectus
would conflict with the information in the Registration Statement, the Statutory Prospectus or the
Prospectus or as a result of which such Issuer Free Writing Prospectus, if republished immediately
following such event or development, would include an untrue statement of a material fact or omit
to state any material fact necessary in order to make the statements therein, in the light of the
circumstances then prevailing, not misleading, the Company will give prompt notice thereof to the
Representatives, will promptly amend or supplement such Issuer Free Writing Prospectus to eliminate
or correct such conflict, untrue statement or omission and, if requested by the Representatives,
will prepare and furnish without charge to each Underwriter such amended or supplemented Issuer
Free Writing Prospectus; provided, however, that this representation and warranty shall not apply
to any statements or omissions in an Issuer Free Writing Prospectus made in reliance upon and in
conformity with information furnished in writing to the Company by an Underwriter through the
Representatives expressly for use therein.
6. Conditions of the Obligations of the Underwriters. The obligations of the several
Underwriters to purchase and pay for the Offered Securities will be subject to the accuracy of the
representations and warranties on the part of the Company herein, to the accuracy of the statements
of the Company’s officers made pursuant to the provisions hereof, to the performance by the Company
of its obligations hereunder and to the following additional conditions precedent:
(a) Auditors’ Comfort Letter. At the Applicable Time, the Representatives shall have received
a letter, dated the date of delivery thereof, of Deloitte & Touche LLP confirming that they are
independent public accountants within the meaning of the Securities Act and the applicable
published rules and regulations thereunder and stating to the effect that:
(i) in their opinion the financial statements and any schedules and any summary of
earnings examined by them and included in the General Disclosure Package and the Prospectus
comply as
19
to form in all material respects with the applicable accounting requirements of the
Securities Act and the related published rules and regulations;
(ii) they have performed the procedures specified by the American Institute of
Certified Public Accountants for a review of interim financial information as described in
Statement of Auditing Standards No. 100, Interim Financial Information, on any unaudited
financial statements included in the General Disclosure Package and the Prospectus;
(iii) on the basis of the review referred to in clause (ii) above, a reading of the
latest available interim financial statements of the Company, inquiries of officials of the
Company who have responsibility for financial and accounting matters and other specified
procedures, nothing came to their attention that caused them to believe that:
(A) the unaudited financial statements, if any, and any summary of earnings
included in the General Disclosure Package or the Prospectus do not comply as to form in
all material respects with the applicable accounting requirements of the Securities Act
and the related published rules and regulations or any material modifications should be
made to such unaudited financial statements and summary of earnings for them to be in
conformity with accounting principles generally accepted in Canada;
(B) if any unaudited “capsule” information is contained in the General Disclosure
Package or the Prospectus, the unaudited consolidated sales, operating income, net
income and net income per share amounts or other amounts constituting such “capsule”
information and described in such letter do not agree with the corresponding amounts set
forth in the unaudited consolidated financial statements or were not determined on a
basis substantially consistent with that of the corresponding amounts in the audited
statements of income;
(C) at the date of the latest available balance sheet read by such accountants, or
at a subsequent specified date not more than three business days prior to the date of
the such letter, there was any change in the capital stock or any increase in short-term
indebtedness or long-term debt of the Company and its consolidated subsidiaries or, at
the date of the latest available balance sheet read by such accountants, there was any
decrease in consolidated net assets, as compared with amounts shown on the latest
balance sheet included in the General Disclosure Package and the Prospectus; or
(D) for the period from the closing date of the latest income statement included in
the General Disclosure Package and the Prospectus to the closing date of the latest
available income statement read by such accountants there were any decreases, as
compared with the corresponding period of the previous year, in consolidated sales,
operating income or net income;
except in all cases set forth in clauses (C) and (D) above for changes, increases or
decreases which the General Disclosure Package and the Prospectus disclose have occurred or
may occur or which are described in such letter; and
(iv) they have compared specified dollar amounts (or percentages derived from such
dollar amounts) and other financial information contained in the General Disclosure Package,
the Prospectus and each Issuer Free Writing Prospectus (other than any Free Writing
Prospectus that is a “bona fide electronic road show” as defined in Rule 433(h) under the
Securities Act) (in each case to the extent that such dollar amounts, percentages and other
financial information are derived from the general accounting records of the Company and its
subsidiaries subject to the
20
internal controls of the Company’s accounting system or are derived directly from such
records by analysis or computation) with the results obtained from inquiries, a reading of
such general accounting records and other procedures specified in such letter and have found
such dollar amounts, percentages and other financial information to be in agreement with
such results, except as otherwise specified in such letter.
All financial statements and schedules included in material incorporated by reference into the
Statutory Prospectus and the Prospectus shall be deemed included in the Statutory Prospectus and
the Prospectus for purposes of this subsection.
(b) Prospectus Filed; No Stop Order. The Prospectus shall have been filed with the Commission
pursuant to Rule 424(b) under the Securities Act and within the applicable time period prescribed
for such filing by the rules and regulations under the Securities Act and in accordance with
Section 4(a) of this Agreement. The final term sheet contemplated by Section 4(c) hereof, and any
other material required to be filed by the Company pursuant to Rule 433(d) under the Securities
Act, shall have been filed with the Commission within the applicable time periods prescribed for
such filings by Rule 433 under the Securities Act. No stop order suspending the effectiveness of
the Registration Statement or of any part thereof shall have been issued and no proceedings for
that purpose shall have been instituted or, to the knowledge of the Company or any Underwriter,
shall be threatened by the Commission and no notice of objection of the Commission to the use of
the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under
the Securities Act shall have been received; no stop order suspending or preventing the use of the
Prospectus or any Issuer Free Writing Prospectus shall have been initiated or threatened by the
Commission; and all requests for additional information on the part of the Commission shall have
been complied with to the Representatives’ reasonable satisfaction.
(c) No Material Adverse Change. Subsequent to the execution of the Terms Agreement, there
shall not have occurred (i) any change, or any development or event involving a prospective change,
in the financial condition, business, properties or results of operations of the Company and its
subsidiaries taken as one enterprise that, in the judgment of the Representatives, is material and
adverse and makes it impractical or inadvisable to proceed with completion of the public offering
or the sale of and payment for the Offered Securities; (ii) any downgrading in the rating of any
debt securities of the Company by any “nationally recognized statistical rating organization” (as
defined for purposes of Rule 436(g) under the Securities Act), or any public announcement that any
such organization has under surveillance or review its rating of any debt securities of the Company
(other than an announcement with positive implications of a possible upgrading, and no implication
of a possible downgrading, of such rating); (iii) any suspension or material limitation of trading
in securities generally on the New York Stock Exchange or The Toronto Stock Exchange or any setting
of minimum prices for trading on such exchanges, or any suspension of trading of any securities of
the Company on the New York Stock Exchange or The Toronto Stock Exchange; (iv) any banking
moratorium declared by U.S. Federal, New York or Canadian Federal authorities; or (v) any outbreak
or escalation of major hostilities in which the United States or Canada is involved, any
declaration of war by Congress or the Government of Canada or any other substantial national or
international calamity or emergency if, in the judgment of the Representatives, the effect of any
such outbreak, escalation, declaration, calamity or emergency makes it impractical or inadvisable
to proceed with completion of the public offering or the sale of and payment for the Offered
Securities.
(d) Opinion of Canadian and U.S. Counsel to the Company. The Representatives shall have
received an opinion, dated the Closing Date, of Stikeman Elliott LLP, Canadian counsel to the
Company, substantially in the form included as Exhibit A, and an opinion, dated the Closing Date,
of Xxxxx Day, United States counsel to the Company, substantially in the form included as Exhibit
B.
21
(e) Opinion of Canadian Tax Counsel to the Company. The Representatives shall have received an
opinion, dated the Closing Date, of Canadian tax counsel to the Company, to the effect that,
subject to the assumptions, limitations, qualifications and conditions set out therein, the
statements made in the General Disclosure Package and the Prospectus relating to Canadian federal
income tax laws under the heading “Canadian Federal Income Tax Considerations”, insofar as they
relate to matters of Canadian federal income tax law, constitute a fair summary of the matters so
discussed and applicable to the holders of Offered Securities described therein.
(f) Opinion of United States Tax Counsel to the Company. The Representatives shall have
received an opinion, dated the Closing Date, of United States tax counsel to the Company, to the
effect that, subject to the assumptions, limitations, qualifications and conditions set out
therein, the statements made in the General Disclosure Package and the Prospectus under the heading
“United States Federal Income Tax Considerations”, insofar as such statements purport to summarize
certain federal income tax laws of the United States, constitute a fair summary of the principal
U.S. federal income tax consequences of an investment in the Offered Securities.
(g) Opinion of Counsel to the Underwriters. The Representatives shall have received from
Skadden, Arps, Slate, Xxxxxxx & Xxxx LLP, counsel for the Underwriters, such opinion or opinions,
dated the Closing Date, with respect to such matters as the Representatives may require, and the
Company shall have furnished to such counsel such documents as they request for the purpose of
enabling them to pass upon such matters.
(h) Officers’ Certificate. The Representatives shall have received a certificate, dated the
Closing Date, of the President or any Vice President and a principal financial or accounting
officer of the Company in which such officers, to the best of their knowledge after reasonable
investigation, shall state on behalf of the Company that the representations and warranties of the
Company in this Agreement are true and correct, that the Company has complied with all agreements
and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the
Closing Date, that no stop order suspending the effectiveness of the Registration Statement or of
any part thereof has been issued and no proceedings for that purpose have been instituted or, to
their knowledge, are threatened by the Commission and that, subsequent to the date of the most
recent financial statements in the General Disclosure Package and the Prospectus, there has been no
material adverse change, nor any development or event involving a prospective material adverse
change, in the financial condition, business, properties or results of operations of the Company
and its subsidiaries taken as one enterprise, except as set forth in or contemplated by the
Registration Statement, the Statutory Prospectus or the Prospectus or as described in such
certificate.
(i) Bring-down Auditors’ Comfort Letter. The Representatives shall have received a letter,
dated the Closing Date, of Deloitte & Touche LLP which meets the requirements of subsection (a) of
this Section, except that the specified date referred to in such subsection will be a date not more
than three days prior to the Closing Date for the purposes of this subsection.
The Company will furnish the Representatives with such conformed copies of such opinions,
certificates, letters and documents as the Representatives reasonably request. The Lead Underwriter
may in its sole discretion waive on behalf of the Underwriters compliance with any conditions to
the obligations of the Underwriters under this Agreement and the Terms Agreement.
7. Indemnification and Contribution. (a) Indemnification of the Underwriters by the Company.
The Company will indemnify and hold harmless each Underwriter, its partners, directors and officers
and each person, if any, who controls such Underwriter within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act (each, an “Indemnified Party”), against any
losses, claims, damages or
22
liabilities, joint or several, to which such Indemnified Party may become subject, under the
Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in
respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue
statement of any material fact contained in the Registration Statement, or any amendment thereto,
or the omission or alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading or (ii) any untrue statement or alleged
untrue statement of any material fact contained in the Base Prospectus, any Preliminary Prospectus,
the Statutory Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer
Free Writing Prospectus or any “issuer information” filed or required to be filed pursuant to Rule
433(d) under the Securities Act, or the omission or alleged omission to state therein a material
fact required to be stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading, and will reimburse each Indemnified Party
for any legal or other expenses reasonably incurred by such Indemnified Party in connection with
investigating or defending against any loss, claim, damage, liability, action, litigation,
investigation or proceeding whatsoever (whether or not such Indemnified Party is a party thereto),
whether threatened or commenced, based upon any such untrue statement or omission, or any such
alleged untrue statement or omission, as such expenses are incurred; provided, however, that the
Company will not be liable in any such case to the extent that any such loss, claim, damage or
liability arises out of or is based upon any untrue statement or alleged untrue statement in or
omission or alleged omission from any of such documents in reliance upon and in conformity with
written information furnished to the Company by any Underwriter through the Representatives, if
any, specifically for use therein, it being understood and agreed that the only such information
furnished by any Underwriter consists of the information described as such in the Terms Agreement.
(b) Indemnification of the Company by the Underwriters. Each Underwriter will severally and
not jointly indemnify and hold harmless the Company, its directors and officers and each person, if
any, who controls the Company within the meaning of Section 15 of the Securities Act and Section 20
of the Exchange Act (each, an “Underwriter Indemnified Party”), against any losses, claims, damages
or liabilities to which such Underwriter Indemnified Party may become subject, under the Securities
Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect
thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of any
material fact contained in the Registration Statement, or any amendment thereto, or the omission or
alleged omission to state therein a material fact required to be stated therein or necessary to
make the statements therein not misleading or (ii) any untrue statement or alleged untrue statement
of any material fact contained in the Base Prospectus, any Preliminary Prospectus, the Statutory
Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing
Prospectus, or the omission or the alleged omission to state therein a material fact required to be
stated therein or necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading, in each case to the extent, but only to the extent, that such
untrue statement or alleged untrue statement or omission or alleged omission was made in reliance
upon and in conformity with written information furnished to the Company by such Underwriter
through the Representatives, if any, specifically for use therein, and will reimburse any legal or
other expenses reasonably incurred by such Underwriter Indemnified Party in connection with
investigating or defending any such loss, claim, damage, liability, action, litigation,
investigation or proceeding whatsoever (whether or not such Underwriter Indemnified Party is a
party thereto), whether threatened or commenced, based upon any such untrue statement or omission,
or any such alleged untrue statement or omission, as such expenses are incurred, it being
understood and agreed that the only such information furnished by any Underwriter consists of the
information described as such in the Terms Agreement.
(c) Actions Against Parties; Notification. Promptly after receipt by an indemnified party
under this Section of notice of the commencement of any action, such indemnified party will, if a
claim in respect thereof is to be made against the indemnifying party under subsection (a) or (b)
above, notify the
23
indemnifying party of the commencement thereof but the omission so to notify the indemnifying
party will not relieve it from any liability that it may have under subsection (a) or (b) above
except to the extent that it has been materially prejudiced (through the forfeiture of substantive
rights or defenses) by such failure; and provided further that the failure to notify the
indemnifying party shall not relieve it from any liability that it may have to any indemnified
party otherwise than under subsection (a) or (b) above. In case any such action is brought against
any indemnified party and it notifies the indemnifying party of the commencement thereof, the
indemnifying party will be entitled to participate therein and, to the extent that it may wish,
jointly with any other indemnifying party similarly notified, to assume the defense thereof, with
counsel satisfactory to such indemnified party and shall pay the fees and disbursements of such
counsel related to such proceeding. In any such proceeding, any indemnified party shall have the
right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense
of such indemnified party unless (i) the indemnifying party and the indemnified party shall have
mutually agreed to the retention of such counsel or (ii) the named parties to any such proceeding
(including any impleaded parties) include both the indemnifying party and the indemnified party and
representation of both parties by the same counsel would be inappropriate due to actual or
potential differing interests between them. No indemnifying party shall, without the prior written
consent of the indemnified party, effect any settlement of any pending or threatened action in
respect of which any indemnified party is or could have been a party and indemnity could have been
sought hereunder by such indemnified party unless such settlement (i) includes an unconditional
release of such indemnified party from all liability on any claims that are the subject matter of
such action and (ii) does not include a statement as to, or an admission of, fault, culpability or
a failure to act by or behalf of an indemnified party. It is understood that the indemnifying party
shall, in connection with any one action, suit or proceeding or separate but substantially similar
or related actions, suits or proceedings in the same jurisdiction arising out of the same general
allegations or circumstances, be liable for the reasonable fees and expenses of only one separate
firm of attorneys (in addition to any local counsel) at any time for all such indemnified parties
not having actual or potential differing interests. The indemnifying party shall not be liable for
any settlement of any such action, suit or proceeding effected without its written consent, which
consent shall not be unreasonably withheld.
(d) Contribution. If the indemnification provided for in this Section is unavailable or
insufficient to hold harmless an indemnified party under subsection (a) or (b) above, then each
indemnifying party shall contribute to the amount paid or payable by such indemnified party as a
result of the losses, claims, damages or liabilities referred to in subsection (a) or (b) above (i)
in such proportion as is appropriate to reflect the relative benefits received by the Company on
the one hand and the Underwriters on the other from the offering of the Offered Securities or (ii)
if the allocation provided by clause (i) above is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)
above but also the relative fault of the Company on the one hand and the Underwriters on the other
in connection with the statements or omissions that resulted in such losses, claims, damages or
liabilities as well as any other relevant equitable considerations. The relative benefits received
by the Company on the one hand and the Underwriters on the other shall be deemed to be in the same
proportion as the total net proceeds from the offering (before deducting expenses) received by the
Company bear to the total underwriting discounts and commissions received by the Underwriters. The
relative fault shall be determined by reference to, among other things, whether the untrue or
alleged untrue statement of a material fact or the omission or alleged omission to state a material
fact relates to information supplied by the Company or the Underwriters and the parties’ relative
intent, knowledge, access to information and opportunity to correct or prevent such untrue
statement or omission. The amount paid by an indemnified party as a result of the losses, claims,
damages or liabilities referred to in the first sentence of this subsection (d) shall be deemed to
include any legal or other expenses reasonably incurred by such indemnified party in connection
with investigating or defending any action or claim that is the subject of this subsection (d).
Notwithstanding the provisions of this subsection (d), no Underwriter shall be required to
contribute any amount in excess of the amount by which the total price at which the
24
Offered Securities underwritten by it and distributed to the public were offered to the public
exceeds the amount of any damages which such Underwriter has otherwise been required to pay by
reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty
of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall
be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation. The Underwriters’ obligations in this subsection (d) to contribute are several
in proportion to their respective underwriting obligations and not joint.
(e) Obligations in Addition to Other Liabilities. The obligations of the Company under this
Section shall be in addition to any liability which the Company may otherwise have and shall
extend, upon the same terms and conditions, to each person, if any, who controls any Underwriter
within the meaning of the Securities Act; and the obligations of the Underwriters under this
Section shall be in addition to any liability that the respective Underwriters may otherwise have
and shall extend, upon the same terms and conditions, to each director of the Company, to each
officer of the Company who has signed the Registration Statement and to each person, if any, who
controls the Company within the meaning of the Securities Act.
8. Default of Underwriters. If any Underwriter or Underwriters default in their obligations to
purchase Offered Securities under the Terms Agreement and the aggregate principal amount of Offered
Securities that such defaulting Underwriter or Underwriters agreed but failed to purchase does not
exceed 10% of the total principal amount of Offered Securities, the Lead Underwriter may make
arrangements satisfactory to the Company for the purchase of such Offered Securities by other
persons, including any of the Underwriters, but if no such arrangements are made by the Closing
Date, the non-defaulting Underwriters shall be obligated severally, in proportion to their
respective commitments under the Terms Agreement (including the provisions of this Agreement), to
purchase the Offered Securities that such defaulting Underwriters agreed but failed to purchase. If
any Underwriter or Underwriters so default and the aggregate principal amount of Offered Securities
with respect to which such default or defaults occur exceeds 10% of the total principal amount of
Offered Securities and arrangements satisfactory to the Lead Underwriter and the Company for the
purchase of such Offered Securities by other persons are not made within 36 hours after such
default, the Terms Agreement will terminate without liability on the part of any non-defaulting
Underwriter or the Company, except as provided in Section 9. As used in this Agreement, the term
“Underwriter” includes any person substituted for an Underwriter under this Section. Nothing herein
will relieve a defaulting Underwriter from liability for its default. The respective commitments of
the several Underwriters for the purposes of this Section shall be determined without regard to
reduction in the respective Underwriters’ obligations to purchase the principal amounts of the
Offered Securities set forth opposite their names in the Terms Agreement as a result of Delayed
Delivery Contracts entered into by the Company.
9. Survival of Certain Representations and Obligations. The respective indemnities,
agreements, representations, warranties and other statements of the Company or its officers and of
the several Underwriters set forth in or made pursuant to the Terms Agreement (including the
provisions of this Agreement) will remain in full force and effect, regardless of any
investigation, or statement as to the results thereof, made by or on behalf of any Underwriter, the
Company or any of their respective representatives, officers or directors or any controlling
person, and will survive delivery of and payment for the Offered Securities. If the Terms Agreement
is terminated pursuant to Section 8 or if for any reason the purchase of the Offered Securities by
the Underwriters is not consummated, the Company shall remain responsible for the expenses to be
paid or reimbursed by it pursuant to Section 4 and the respective obligations of the Company and
the Underwriters pursuant to Section 7 shall remain in effect. If the purchase of the Offered
Securities by the Underwriters is not consummated for any reason other than because of the
termination of the Terms Agreement pursuant to Section 8 or the occurrence of any event specified
in clause (iii), (iv) or (v) of Section 6(c), the Company will reimburse the Underwriters for
25
all out-of-pocket expenses (including fees and disbursements of counsel) reasonably incurred
by them in connection with the offering of the Offered Securities.
10. Notices. All communications hereunder will be in writing and, if sent to the Underwriters,
will be mailed, delivered or telegraphed and confirmed to them at their address furnished to the
Company in writing for the purpose of communications hereunder or, if sent to the Company, will be
mailed, delivered or telegraphed and confirmed to it at 122 – 0xx Xxxxxx Xxxxx, Xxxxx
000, Xxxxxxxxx, Xxxxxxxxxxxx, Xxxxxx S7K 7G3, Tel.: (000) 000-0000, Fax: (000) 000-0000, Attention:
Chief Financial Officer.
11. Successors. The Terms Agreement (including the provisions of this Agreement) will inure to
the benefit of and be binding upon the Company and such Underwriters as are identified in the Terms
Agreement and their respective successors and the officers and directors and controlling persons
referred to in Section 7, and no other person will have any right or obligation hereunder.
12. Representation of Underwriters. Any Representatives will act for the several Underwriters
in connection with the financing described in the Terms Agreement, and any action under such Terms
Agreement (including the provisions of this Agreement) taken by the Representatives jointly or by
the Lead Underwriter will be binding upon all the Underwriters.
13. Counterparts. The Terms Agreement may be executed in any number of counterparts, each of
which shall be deemed to be an original, but all such counterparts shall together constitute one
and the same Agreement.
14. Applicable Law. This Agreement and the Terms Agreement shall be governed by, and construed
in accordance with, the laws of the State of New York, without regard to the principles of
conflicts of laws.
15. Submission to Jurisdiction. The Company hereby submits to the non-exclusive jurisdiction
of the United States federal and state courts in the Borough of Manhattan in The City of New York
in any suit or proceeding arising out of the Terms Agreement (including the provisions of this
Agreement) or the transactions contemplated thereby. The Company irrevocably appoints CT
Corporation System, 000 Xxxxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx 00000, as its authorized agent in the
Borough of Manhattan in the City of New York upon which process may be served in any such suit or
proceeding, and agrees that service of process upon such agent, and written notice of said service
to the Company by the person serving the same to the address provided in Section 10, shall be
deemed in every respect effective service of process upon the Company in any such suit or
proceeding. The Company further agrees to take any and all action as may be necessary to maintain
such designation and appointment of such agent in full force and effect for a period of six years
from the date of the Terms Agreement.
16. Judgment Currency. The obligation of the Company in respect of any sum due to any
Underwriter shall, notwithstanding any judgment in a currency other than United States dollars, not
be discharged until the first business day following receipt by such Underwriter of any sum
adjudged to be so due in such other currency, on which (and only to the extent that) such
Underwriter may in accordance with normal banking procedures purchase United States dollars with
such other currency; if the United States dollars so purchased are less than the sum originally due
to such Underwriter thereunder, the Company agrees, as a separate and independent obligation and
notwithstanding any such judgment, to indemnify such Underwriter against such loss. If the United
States dollars so purchased are greater than the sum originally due to such Underwriter thereunder,
such Underwriter agrees to pay promptly to the Company an amount equal to the excess of the dollars
so purchased over the sum originally due to such Underwriter thereunder.
26
SCHEDULE A
Subsidiaries
PCS Phosphate Company Inc.
PCS Sales (U.S.A.) Inc.
PCS Nitrogen Fertilizer, L.P.
PCS Nitrogen Trinidad Limited
PCS Sales (U.S.A.) Inc.
PCS Nitrogen Fertilizer, L.P.
PCS Nitrogen Trinidad Limited
SCHEDULE B
POTASH CORPORATION OF SASKATCHEWAN INC.
TERMS AGREEMENT
Debt Securities
[Date]
To: The Underwriters identified herein
Ladies and Gentlemen:
The undersigned Potash Corporation of Saskatchewan Inc. (the “Company”) agrees to sell to the
several Underwriters named in Schedule A hereto for their respective accounts, on and subject to
the terms and conditions of the Underwriting Agreement attached hereto as Exhibit I (the
“Underwriting Agreement”), the following securities (the “Offered Securities”) on the following
terms:
Title:
Principal Amount:
Interest:
Maturity:
Optional Redemption:
Listing:
Delayed Delivery Contracts:
Lock-up Period (pursuant to Section 4(j) of the Underwriting Agreement):
Underwriting Fee: % of principal amount.
Payment by Underwriters: % of principal amount, plus accrued interest, if any, from , 20 .
Expected Reoffering Price: % of principal amount, subject to change by the
Representatives.
Applicable Time: :00 [a.m.][p.m.] (Eastern Time) on the date of this Terms Agreement.
Final Term Sheet: The Company will prepare and file a final term sheet relating to the
Offered Securities as contemplated in Section 4(c) of the Underwriting Agreement.
Closing: :00 [a.m.][p.m.] (Eastern Time) on , 20 , at the offices
of , in Federal (same day) funds.
Settlement and Trading:
Lead Underwriter:
Representatives:
The respective principal amounts of the Offered Securities to be purchased by each of the
Underwriters are set forth opposite their names in Schedule A hereto.
The provisions of the Underwriting Agreement form a part hereof.
The Offered Securities will be made available for checking and packaging at the offices of at least 24 hours prior to the Closing.
For purposes of Sections 2, 5 and 7 of the Underwriting Agreement, the only information
furnished to the Company by any Underwriter for use in the General Disclosure Package or the
Prospectus consists of:
If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company one of the counterparts hereof, whereupon it will become a binding agreement
between the Company and the several Underwriters in accordance with its terms.
Very truly yours, | ||||||
Potash Corporation of Saskatchewan Inc. | ||||||
By: | ||||||
Name: | ||||||
Title: | ||||||
By: | ||||||
Name: | ||||||
Title: |
The foregoing Terms Agreement is hereby confirmed and accepted as of the date first above written. |
||||
By: |
||||
of the several Underwriters |
||||
Name: |
||||
Title: |
SCHEDULE A TO TERMS AGREEMENT
Underwriter | Principal Amount | |||
Total |
||||
SCHEDULE B TO TERMS AGREEMENT
(referred to in Sections 2 and 5 of the Underwriting Agreement)
(referred to in Sections 2 and 5 of the Underwriting Agreement)
1. | Statutory Prospectus included in the General Disclosure Package | |
1. Base Prospectus, dated , 20 , as supplemented by the Preliminary Prospectus Supplement, dated , 20 . | ||
2. | General Use Issuer Free Writing Prospectuses (included in the General Disclosure Package) | |
“General Use Issuer Free Writing Prospectus” includes each of the following documents: | ||
1. Final term sheet, dated , 20 , a copy of which is attached hereto. | ||
3. | Other Information included in the General Disclosure Package | |
The following information is also included in the General Disclosure Package: | ||
1. Electronic road show |
EXHIBIT A
[Form of Opinion of Stikeman Elliott]
EXHIBIT B
[Form of Opinion of Xxxxx Day]
ANNEX I
DELAYED DELIVERY CONTRACT
Debt Securities
Debt Securities
[Date]
POTASH CORPORATION OF SASKATCHEWAN INC.
Ladies and Gentlemen:
The undersigned hereby agrees to purchase from Potash Corporation of Saskatchewan Inc., a
company incorporated under the laws of Canada (the “Company”), and the Company agrees to sell to
the undersigned, as of the date hereof, for delivery on , 20 (the “Delivery
Date”),
$
principal amount of the Company’s % [Notes] due (the “Securities”), offered by the
Company’s Prospectus dated and a Prospectus Supplement dated
relating thereto, receipt of copies of which is hereby acknowledged, at
% of the principal amount thereof plus accrued interest, if any, and on the further terms and
conditions set forth in this Delayed Delivery Contract (this “Contract”).
Payment for the Securities that the undersigned has agreed to purchase for delivery on the
Delivery Date shall be made to the Company or its order in Federal (same day) funds by certified or
official bank check or wire transfer (as specified by the Company) to an account designated by the
Company, at the office of at a.m. on the Delivery Date upon
delivery to the undersigned of the Securities to be purchased by the undersigned in definitive
fully registered form and in such denominations and registered in such names as the undersigned may
designate by written or telegraphic communication addressed to the Company not less than five full
business days prior to the Delivery Date.
It is expressly agreed that the provisions for delayed delivery and payment are for the sole
convenience of the undersigned; that the purchase hereunder of Securities is to be regarded in all
respects as a purchase as of the date of this Contract, except for purposes of determining the
original date of issue under Section 10.08 of the Indenture which the parties hereto acknowledge is
the Delivery Date; that the obligation of the Company to make delivery of and accept payment for,
and the obligation of the undersigned to take delivery of and make payment for, Securities on the
Delivery Date shall be subject only to the conditions that (1) investment in the Securities shall
not at the Delivery Date be prohibited under the laws of any jurisdiction in the United States to
which the undersigned is subject and (2) the Company shall have sold to the Underwriters the total
principal amount of the Securities less the principal amount thereof covered by this and other
similar Contracts. The undersigned represents that its investment in the Securities is not, as of
the date hereof, prohibited under the laws of any jurisdiction to which the undersigned is subject
and which governs such investment.
Promptly after completion of the sale to the Underwriters, the Company will mail or deliver to
the undersigned at its address set forth below notice to such effect, accompanied by copies of the
opinions of counsel for the Company delivered to the Underwriters in connection therewith.
This Contract will inure to the benefit of and be binding upon the parties hereto and their
respective successors, but will not be assignable by either party hereto without the written
consent of the other.
It is understood that the acceptance of any such Contract is in the Company’s sole discretion
and, without limiting the foregoing, need not be on a first-come, first-served basis. If this
Contract is acceptable to the Company, it is requested that the Company sign the form of acceptance
below and mail or deliver one of the counterparts hereof to the undersigned at its address set
forth below. This will become a binding contract between the Company and the undersigned when such
counterpart is so mailed or delivered.
[signature page follows]
Yours very truly, | ||||||
(Name of Purchaser) | ||||||
By | ||||||
(Title of Signatory) | ||||||
(Address of Purchaser) |
Accepted, as of the above date.
POTASH CORPORATION OF SASKATCHEWAN INC.
By |
||||